Magic mushroom compound shows promise for Tough-to-Treat depression and BPD
NCT ID NCT05399498
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 23 times
Summary
This small study tested a single dose of psilocybin, the active ingredient in magic mushrooms, in 9 adults with both major depression and borderline personality disorder. Researchers measured changes in depression and BPD symptoms over time to see if the treatment was safe and helpful. The goal was to explore whether this approach could ease symptoms in people with these overlapping conditions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Chicago
Chicago, Illinois, 60637, United States
Conditions
Explore the condition pages connected to this study.